Payors Adopt McKesson's Automated InterQual Molecular Dx System to Avoid Inaccurate Coverage Decisions

"As the prevalence [of molecular diagnostics] grows, plans realize they're paying for diagnostic/genomic tests without guidance as to when the tests are appropriate," McKesson's Matthew Zubiller said, discussing the increasing usage of the company's InterQual Molecular Diagnostics Criteria.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.